Doxacurium chloride: a preliminary clinical trial.
The onset, duration of action and reversibility of doxacurium were studied in 27 anaesthetized patients, using doses of 37.5 micrograms kg-1 (1.5 x ED95) and 62.5 micrograms kg-1 (2.5 x ED95). Onset was slow and, whilst tracheal intubation was always possible 3 or 4 min after injection, the conditions were not ideal. With the higher dose a mean 97.6 (SD 5.2)% block of the response of adductor pollicis to ulnar nerve stimulation was obtained in 9.85 (6.17) min and recovery of the integrated EMG response to 20% of control took 102 min (42 min). After these initial doses, when incremental doses were given there was no sign of cumulation of effect. Antagonism of block with edrophonium 1 mg kg-1, whilst fast in onset, was rarely complete; with neostigmine 50 micrograms kg-1 antagonism was satisfactory. No adverse haemodynamic effect was seen, although a gradual onset of bradycardia, which responded to atropine or glycopyrrolate, was noted in 12 of the patients. No histamine release or other adverse effects were noted.
Scott
R P
RP
Shackleton Department of Anaesthetics, University, Southhampton General Hospital.
Norman
J
J
D000328:Adult; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004491:Edrophonium / Q000494:pharmacology; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007432:Intraoperative Period; D007546:Isoquinolines / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D009388:Neostigmine / Q000494:pharmacology; D009469:Neuromuscular Junction / Q000187:drug effects; D003473:Neuromuscular Nondepolarizing Agents; D013997:Time Factors
D007546:Isoquinolines; D003473:Neuromuscular Nondepolarizing Agents; D009388:Neostigmine; D004491:Edrophonium; C049429:doxacurium